[Insulin therapy of type 2 diabetes mellitus (Update 2019)].

Monika Lechleitner, Martin Clodi, Heidemarie Abrahamian, Helmut Brath, Johanna Brix, Heinz Drexel, Peter Fasching, Bernhard Föger, Claudia Francesconi, Elke Fröhlich-Reiterer, Jürgen Harreiter, Sabine E Hofer, Friedrich Hoppichler, Joakim Huber, Susanne Kaser, Alexandra Kautzky-Willer, Bernhard Ludvik, Anton Luger, Julia K Mader, Bernhard Paulweber (Co-author)Thomas Pieber, Rudolf Prager, Birgit Rami-Merhar, Michael Resl, Michaela Riedl, Michael Roden, Christoph H Saely, Christian Schelkshorn, Guntram Schernthaner, Harald Sourij, Lars Stechemesser (Co-author), Harald Stingl, Hermann Toplak, Thomas C Wascher, Raimund Weitgasser (Co-author), Yvonne Winhofer-Stöckl, Sandra Zlamal-Fortunat

Research output: Contribution to journalOriginal Articlepeer-review

2 Citations (Web of Science)
Original languageGerman
Pages (from-to)39-46
JournalWIENER KLINISCHE WOCHENSCHRIFT
Volume131
Issue numberSuppl 1
DOIs
Publication statusPublished - 2019

Keywords

  • LONGACTING BASAL INSULIN
  • GLARGINE 300 U/ML
  • ACTING INSULIN
  • CARDIOVASCULAR OUTCOMES
  • BOLUS TREATMENT
  • OPEN-LABEL
  • HYPOGLYCEMIA
  • EFFICACY
  • DEGLUDEC
  • ASPART

Cite this